Diablo Clinical Research
Diablo Clinical Research
Walnut Creek, California, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-05 | NCT07684235 | |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-30 | NCT07754461 | |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06858839 | |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT06783309 | |
| A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | Acute Migraine | Recruiting | Phase 3 | 2026-08-27 | NCT07674654 | |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-08-21 | NCT07136012 | |
| A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Recruiting | Phase 3 | 2026-08-20 | NCT07645924 | |
| Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Not applicable | 2026-04-09 | NCT07296276 | |
| Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus | Dyssomnias, Nutritional and Metabolic Diseases, Sleep Disorders, Intrinsic, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, insomnia, metabolic disease, nervous system disorder, psychiatric disorder, sleep-wake disorder, type 1 diabetes mellitus | Active, not recruiting | Not applicable | 2025-08-27 | NCT06627517 | |
| Using Signos mHealth Platform in Adults for Weight Management | Body Weight, Body Weight Changes, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, glucose metabolism disease, hyperinsulinism, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Not applicable | 2024-10-08 | NCT06214221 |